MOR News and Press, MorphoSys AG From 06/02/21

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

MorphoSys upgraded at Morgan Stanley citing the potential of MonjuviMorphoSys (MOR) has lost ~23.8% in the year so far. Noting that the pullback has brought the shares towards its bear case value, Morgan Stanley analysts have upgraded the stock to overweight from equal-weight.The price target...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. Eastern...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi (R) ) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 202...

Incyte (NASDAQ:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHO...

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab...

MorphoSys AG (MOR) Q1 2021 Earnings Conference Call May 06, 2021 08:00 AM ET Company Participants Julia Neugebauer - Senior Director of Investor Relations Jean-Paul Kress - Chief Executive Officer Roland Wandeler - Chief Operating Officer Sung Lee - Chief Financial Officer Malte Peters - Chie...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q1 2021 Earnings Call May 6, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q1 2021 Earnings Call Transcript

The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q1 earnings call. For further details see: MorphoSys AG 2021 Q1 - Results - Earnings Call Presentation

Cost of Sales: In the first three months of 2021, cost of sales increased to € 5.0 million (3M 2020: € 3.3 million). Research and Development (R&D) Expenses: In the first three months of 2021, research and development expenses were € 33.3 million (3M 2020: €...